Stock 688739 LIAONING CHENGDA BIOTECHNOLOGY CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Liaoning Chengda Biotechnology Co.,Ltd.

Equities

688739

CNE100004ZP2

Pharmaceuticals

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-05-21 pm EDT 		5-day change 1st Jan Change
28.15 CNY -0.11% Intraday chart for Liaoning Chengda Biotechnology Co.,Ltd. -0.04% -13.41%
May. 20 Wall Street Cues, Central Bank Outlooks Lift Asian Stock Markets MT
Apr. 29 Liaoning Chengda Biotechnology Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Valuation

Fiscal Period: December 2022 2023 2024 2025 2026
Capitalization 1 12,668 13,539 11,395 - -
Enterprise Value (EV) 1 12,668 13,539 11,395 11,395 11,395
P/E ratio 17.7 x - - - -
Yield - - - - -
Capitalization / Revenue - 7.74 x 6.43 x 6.1 x 5.6 x
EV / Revenue - 7.74 x 6.43 x 6.1 x 5.6 x
EV / EBITDA - 19.3 x 18.4 x 17.7 x 16.5 x
EV / FCF - - - - -
FCF Yield - - - - -
Price to Book - - 1.21 x 1.16 x 1.12 x
Nbr of stocks (in thousands) 416,450 416,450 412,856 - -
Reference price 2 30.42 32.51 28.15 28.15 28.15
Announcement Date 2/24/23 2/23/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2022 2023 2024 2025 2026
Net sales 1 - 1,750 1,771 1,867 2,034
EBITDA 1 - 701.7 620 645 689
EBIT 1 - - 543 568 609
Operating Margin - - 30.66% 30.42% 29.94%
Earnings before Tax (EBT) - - - - -
Net income 714.8 - - - -
Net margin - - - - -
EPS 1.720 - - - -
Free Cash Flow - - - - -
FCF margin - - - - -
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share - - - - -
Announcement Date 2/24/23 2/23/24 - - -
1CNY in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2022 2023 2024 2025 2026
Net Debt - - - - -
Net Cash position - - - - -
Leverage (Debt/EBITDA) - - - - -
Free Cash Flow - - - - -
ROE (net income / shareholders' equity) - 4.84% 4.8% 4.8% 5%
ROA (Net income/ Total Assets) - 4.66% 4.5% 4.6% 4.7%
Assets - - - - -
Book Value Per Share 1 - - 23.40 24.20 25.10
Cash Flow per Share - - - - -
Capex 2 - 552 148 149 170
Capex / Sales - 31.54% 8.36% 7.98% 8.36%
Announcement Date 2/24/23 2/23/24 - - -
1CNY2CNY in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
28.15 CNY
Average target price
32 CNY
Spread / Average Target
+13.68%
Consensus

Annual profits - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
LIAONING CHENGDA BIOTECHNOLOGY CO.,LTD. Stock Liaoning Chengda Biotechnology Co.,Ltd.
-13.41% 1.61B
CSL LIMITED Stock CSL Limited
-1.62% 89.22B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+2.24% 40.49B
BIOGEN INC. Stock Biogen Inc.
-12.97% 32.79B
UCB Stock UCB
+63.50% 26.23B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-20.71% 14.52B
INCYTE CORPORATION Stock Incyte Corporation
-7.31% 13.09B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-42.60% 11.6B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-12.64% 11.5B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+5.47% 8.82B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. 688739 Stock
  4. Financials Liaoning Chengda Biotechnology Co.,Ltd.